University of Kragujevac and Belgrade
Serbia will make a drug for SMA: It will be cheaper and more effective than Zolgensma
The development of a significantly cheaper and more effective drug to alleviate the symptoms of spinal muscular atrophy in infants is the goal of the SMAIPROTACs project, which is financed by the Science Fund of Serbia within the Prizma program.